GRAIL (NASDAQ:GRAL) Coverage Initiated at Piper Sandler

Analysts at Piper Sandler assumed coverage on shares of GRAIL (NASDAQ:GRAL) in a research note issued to investors on Friday, Marketbeat.com reports. The firm set a “neutral” rating and a $54.00 price target on the stock. Piper Sandler’s price target would suggest a potential upside of 18.34% from the stock’s previous close.

A number of other brokerages have also recently weighed in on GRAL. Morgan Stanley reduced their target price on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Canaccord Genuity Group reduced their target price on shares of GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a report on Friday, February 20th. Mizuho initiated coverage on shares of GRAIL in a report on Friday. They set a “neutral” rating and a $58.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Finally, Robert W. Baird set a $82.00 target price on shares of GRAIL in a report on Friday, February 20th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $68.63.

GRAIL Stock Performance

Shares of NASDAQ:GRAL opened at $45.63 on Friday. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -4.08 and a beta of 4.62. GRAIL has a 1-year low of $22.30 and a 1-year high of $118.84. The company has a 50 day moving average price of $63.91 and a 200 day moving average price of $79.76.

GRAIL (NASDAQ:GRAL) last issued its earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.33) by $0.89. The firm had revenue of $43.60 million during the quarter, compared to analysts’ expectations of $43.33 million. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. On average, sell-side analysts expect that GRAIL will post -15.15 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Robert P. Ragusa sold 123,502 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $6,165,219.84. Following the completion of the transaction, the chief executive officer owned 518,582 shares of the company’s stock, valued at approximately $25,887,613.44. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Aaron Freidin sold 45,806 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the completion of the transaction, the chief financial officer directly owned 260,669 shares of the company’s stock, valued at $13,012,596.48. This represents a 14.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 310,267 shares of company stock valued at $15,485,396. Company insiders own 1.85% of the company’s stock.

Hedge Funds Weigh In On GRAIL

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC boosted its stake in GRAIL by 73.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock worth $200,510,000 after purchasing an additional 993,684 shares during the period. Baker BROS. Advisors LP boosted its stake in GRAIL by 27.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock worth $178,484,000 after purchasing an additional 455,208 shares during the period. Vanguard Group Inc. boosted its stake in GRAIL by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock worth $169,535,000 after purchasing an additional 163,790 shares during the period. State Street Corp boosted its stake in GRAIL by 38.8% in the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock worth $156,418,000 after purchasing an additional 510,546 shares during the period. Finally, Morgan Stanley boosted its stake in GRAIL by 63.8% in the 4th quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock worth $129,385,000 after purchasing an additional 588,647 shares during the period.

GRAIL News Summary

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Analyst consensus remains constructive: Street coverage still shows an average rating of “Moderate Buy” with a consensus price target around $72.83, implying meaningful upside from current levels. Article Title
• Neutral Sentiment: Mizuho initiated coverage with a “neutral” rating and a $58 price target (roughly mid‑teens to low‑20s % upside vs. current quoted levels); the call is cautious and reflects uncertainty rather than outright bullishness. Article Title
• Neutral Sentiment: Piper Sandler also initiated coverage with a “neutral” rating and a $54 price target, signaling analyst caution and limited near‑term conviction. Article Title
• Negative Sentiment: Reported study setback: coverage initiation notes reference a recent study disappointment that prompted the neutral stances — clinical execution and near‑term data risk are now front and center for investors. Article Title
• Negative Sentiment: Insider selling by senior management: CEO, President and CFO sold sizable blocks on April 8 (CEO ~123,502 shares; President ~61,665; CFO ~45,806), materially reducing their holdings — a strong negative signal to the market and a likely contributor to downward pressure. Article Title

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.